| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Notoginsenoside Fa targets multiple signaling pathways. It is known to regulate inflammatory pathways and protect cells from oxidative stress. It also shows significant neurite outgrowth enhancing activities in human neuroblastoma SK-N-SH cells. Furthermore, it can improve cardiovascular function by enhancing circulation and reducing vascular damage, and it inhibits tumor cell proliferation while promoting apoptosis.
|
|---|---|
| ln Vitro |
In vitro, Notoginsenoside Fa exhibits potent bioactivity. It shows significant neurite outgrowth enhancing activities in human neuroblastoma SK-N-SH cells, inducing neurite outgrowth by 147.0% compared to control at a concentration of 100 µM after 5 days. This neurotrophic activity suggests its potential in treating neurodegenerative diseases. It also demonstrates antioxidant and anti-inflammatory effects in various cell-based assays.
|
| ln Vivo |
In vivo, the pharmacological effects of Notoginsenoside Fa are inferred from studies on Panax notoginseng extracts. It is believed to contribute to the plant's traditional use in improving cardiovascular function and treating inflammation. Its ability to activate and recover the function of degenerated brain tissue has been suggested, highlighting its potential for neuroprotective applications.
|
| Enzyme Assay |
The in vitro receptor binding assay for Notoginsenoside Fa is not well-defined for a specific receptor. Its activity is typically evaluated in functional cell-based assays. For instance, its neurite outgrowth activity is assayed by treating SK-N-SH cells with the compound and then measuring the length and number of neurites per cell by microscopy, quantifying the effect relative to a control.
|
| Cell Assay |
In vitro cell culture studies are a primary method for evaluating Notoginsenoside Fa's activity. Human neuroblastoma SK-N-SH cells are a common model for assessing its neurotrophic and neuroprotective effects. Cells are treated with various concentrations of the compound, and endpoints such as neurite outgrowth, cell viability (via MTT), and expression of neuronal markers are measured by immunocytochemistry or Western blotting.
|
| Animal Protocol |
In vivo animal models for Notoginsenoside Fa are not specifically established. However, studies on Panax notoginseng saponins often utilize rodent models of ischemic stroke, Alzheimer's disease, or cardiovascular disease. In these models, the compound or extract is administered orally or intraperitoneally, and behavioral, biochemical, and histopathological outcomes are assessed to evaluate its neuroprotective and cardioprotective efficacy.
|
| ADME/Pharmacokinetics |
Notoginsenoside Fa is a large, highly polar molecule with poor oral bioavailability. Like other PPD-type saponins, it is poorly absorbed in its intact form. Its primary metabolic pathway involves deglycosylation by gut microbiota to produce smaller, more bioavailable metabolites. It is stored as a powder at -20°C and is soluble in DMSO and other organic solvents.
|
| Toxicity/Toxicokinetics |
Toxicological data for Notoginsenoside Fa are limited. As a research compound, it is not intended for human use. While it is generally considered to have low toxicity, its cytotoxic effects on tumor cells suggest it could have significant biological activity at higher concentrations. Comprehensive in vivo toxicity studies are not available for this specific compound.
|
| References |
|
| Additional Infomation |
Panax notoginseng saponin Fa has been reported in Panax notoginseng, and data is available.
Notoginsenoside Fa is a research compound and analytical standard, not approved for clinical use. It is a valuable tool for studying the pharmacology of Panax notoginseng and for investigating the therapeutic potential of PPD-type saponins in neurological and cardiovascular diseases. Its significant neurite outgrowth activity makes it a promising lead compound for drug discovery in neurodegeneration. |
| Molecular Formula |
C59H100O27
|
|---|---|
| Molecular Weight |
1241.4091
|
| Exact Mass |
1240.65
|
| CAS # |
88100-04-3
|
| PubChem CID |
75054973
|
| Appearance |
White to off-white solid powder
|
| Density |
1.48±0.1 g/cm3
|
| Melting Point |
235 - 240 °C
|
| LogP |
-1.3
|
| Hydrogen Bond Donor Count |
17
|
| Hydrogen Bond Acceptor Count |
27
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
86
|
| Complexity |
2270
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HERICYNRBVMDFO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C59H100O27/c1-24(2)10-9-14-59(8,86-52-47(76)42(71)40(69)31(82-52)23-78-50-46(75)41(70)37(66)28(19-60)79-50)25-11-16-58(7)35(25)26(63)18-33-56(5)15-13-34(55(3,4)32(56)12-17-57(33,58)6)83-53-48(43(72)38(67)29(20-61)80-53)85-54-49(44(73)39(68)30(21-62)81-54)84-51-45(74)36(65)27(64)22-77-51/h10,25-54,60-76H,9,11-23H2,1-8H3
|
| Chemical Name |
2-[[6-[2-[3-[3-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-12-hydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~80.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8055 mL | 4.0277 mL | 8.0554 mL | |
| 5 mM | 0.1611 mL | 0.8055 mL | 1.6111 mL | |
| 10 mM | 0.0806 mL | 0.4028 mL | 0.8055 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
